|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
| Information provided by: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00659607 |
Purpose
This PMS study aims to review the followings by investigating the actual practice of MicardisPlus Tablet on the market:
| Condition | Phase |
|
Hypertension |
Phase IV |
| MedlinePlus related topics: | High Blood Pressure |
| ChemIDplus related topics: | Telmisartan Telmisartan-Hydrochlorothiazide |
| Study Type: | Observational |
| Official Title: | PMS Study of MicardisPlus Tablet |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
patients diagnosed as essential hypertension
EXCLUSION CRITERIA:
n/a
Contacts and Locations| Contact: Boehringer Ingelheim Study Coordinator | clintriage@rdg.boehringer-ingelheim.com |
| Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Busan, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Seoul, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Gyeonggido, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Gwangju, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Daegu, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Daejeon, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Chungnam, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Incheon, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Jeju, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Jeonnam, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Jeonbuk, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Ulsan, Korea, Republic of | |||||
| Boehringer Ingelheim | Recruiting | ||||
| Gangwondo, Korea, Republic of | |||||
| Boehringer Ingelheim Pharmaceuticals |
| Study Chair: | Boehringer Ingelheim Study Coordinator | B.I. Korea Ltd. |
More Information
| Study ID Numbers: | 502.475 |
| First Received: | April 10, 2008 |
| Last Updated: | July 25, 2008 |
| ClinicalTrials.gov Identifier: | NCT00659607 |
| Health Authority: | Korea, Republic of: KOREA Food and Drug Administration (KFDA) |
|
|